Skip to product information
1 of 2

Boehringer Ingelheim

Express FP 5-VL5 HB

Express FP 5-VL5 HB

Regular price $26.27 USD
Regular price Sale price $26.27 USD
Sale Sold out
Shipping calculated at checkout.
NOTIFY ME WHEN IN STOCK
Size

Please see shipping information regarding vaccines before placing order.

Modified-live virus for vaccination of healthy cows and heifers prior to breeding for prevention of persistently infected calves caused by BVD Types 1&2, including Type 1b; and as an aid in prevention of abortion due to IBR; for prevention of urinary shedding of L. hardjo-bovis; as an aid in prevention of respiratory disease caused by IBR, BVD Types 1&2 and BRSV; as an aid in reduction of respiratory disease caused by PI3, and as an aid in reduction of infertility, delayed conception or abortion caused by Campylobacter fetus var. venerealis and leptospirosis caused by the 5 most common strains of Lepto. IBR, BVD Types I and II, PI3, BRSV, Vibrio and 5 strains of Lepto including hardjo-bovis. Give 2 ml SQ or IM. For primary vaccination, give about 4 weeks prior to breeding and booster in 14-28 days. Safe for pregnant cows or calves nursing pregnant cows, providing they were vaccinated pre-breeding according to label directions with any Express® FP 5-VL5 HB vaccine. Calves vaccinated before 6 months of age should be revaccinated at 6 months. Annual booster is recommended.

Precautions
Store out of direct sunlight at 35-46°F (2-8°C). Do not freeze. Do not mix with other products, except as specified on the label. Use entire contents when first opened. Do not vaccinate within 21 days before slaughter. Injection site swelling may occur. Stressed cattle should not be vaccinated. In case of anaphylactoid reaction, administer epinephrine. In case of human exposure, contact a physician. Inactivate unused contents before disposal. Fetal health risks associated with vaccination of pregnant animals with this vaccine cannot be unequivocally determined by clinical trials conducted for licensure. Appropriate strategies to address the risks associated with vaccine use in pregnant animals should be discussed with a veterinarian. No vaccine can be expected to have 100% efficacy under all conditions. A small number of calves persistently infected with BVD may have a devastating effect on herd health.

Manufacturer and/or Label Information

BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
3239 SATELLITE BLVD., BLDG 500, DULUTH, GA, 30096
Telephone: 800-325-9167
Customer Service: 800-243-0127
Fax: 816-236-2717
Website: www.boehringer-ingelheim.com
THIS SERVICE AND DATA ARE PROVIDED "AS IS". DVMetrics assumes no liability, and each user assumes full risk, responsibility, and liability, related to its use of the DVMetrics service and data. See the Terms of Use for further details.
EXPRESS® FP 5-VL5 HB

Boehringer Ingelheim Animal Health

Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine

Modified Live Virus

Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin

BEEF & DAIRY CATTLE

Indications: This product has been shown to be effective for the vaccination of healthy cattle, including pregnant cows, against reproductive and respiratory disease due to infectious bovine rhinotracheitis (IBR) and bovine virus diarrhea types 1 and 2 (BVD1 & BVD2); against respiratory disease due to parainfluenza 3 (PI3) and bovine respiratory syncytial virus (BRSV); against reproductive disease due to Campylobacter fetus var. venerealis; and against Leptospira canicola, L. grippotyphosa, L. hardjo, L. icterohaemorrhagiae, and L. pomona. This product was licensed prior to the requirement to establish a minimum age for use. The duration of immunity against IBR-induced abortion and against BVD1 & BVD2, including persistently infected calves, is at least 12 months. The duration for the remaining organisms has not been determined. For more information regarding efficacy and safety data, go to productdata.aphis.usda.gov.

This product has also been shown to be effective against abortion due to IBR; against persistently infected calves due to BVD1 & BVD2; against infertility, delayed conception, or abortion due to C. fetus var. venerealis; and against urinary shedding of L. borgpetersenii serovar hardjo (type hardjo-bovis). Vaccinated animals subsequently exposed to L. borgpetersenii serovar hardjo (type hardjo-bovis) have been shown to clear renal infections within 8 weeks of exposure. This vaccine may be used in pregnant cows or calves nursing pregnant cows provided the cows were vaccinated pre-breeding, according to label instructions, with any Express® FP vaccine within the past 12 months.

Composition: The amber glass vial contains IBR, BVD1 (Singer 1a cytopathic), BVD2 (296 cytopathic), PI3, and BRSV modified live viruses (MLV). The plastic vial contains C. fetus and the Leptospira organisms listed, in an adjuvant system. Neomycin and thimerosal added as preservatives.

Directions and dosage: Mix the accompanying bottle of diluent. Rehydrate the vaccine by aseptically adding the diluent to the vaccine vial. Mix well and use immediately. Using aseptic technique, inject 2 mL subcutaneously or intramuscularly. For cows or heifers, vaccinate at or about 4 weeks prior to breeding. If using subcutaneous route, inject in front of the shoulder and midway of the neck, away from the suprascapular lymph node. If initial vaccination, repeat with any Express® vaccine containing C. fetus, Leptospira and BRSV MLV in 14 to 28 days. Contact your veterinarian or the manufacturer for information on revaccination frequency.

Precautions: Store out of direct sunlight at 35-46°F (2-8°C). Do not freeze. Do not mix with other products, except as specified on the label. Use entire contents when first opened. Do not vaccinate within 21 days before slaughter. Injection site swelling may occur. Stressed cattle should not be vaccinated. In case of anaphylactoid reaction, administer epinephrine. In case of human exposure, contact a physician. Inactivate unused contents before disposal.

Fetal health risks associated with vaccination of pregnant animals with this vaccine cannot be unequivocally determined by clinical trials conducted for licensure. Appropriate strategies to address the risks associated with vaccine use in pregnant animals should be discussed with a veterinarian.

No vaccine can be expected to have 100% efficacy under all conditions. A small number of calves persistently infected with BVD may have a devastating effect on herd health.

Note: It is possible that healthy-appearing cattle can be persistently infected with or incubating virulent BVD virus at the time of vaccination. In view of these findings and suggested causes, BVD vaccine is contraindicated in persistently infected cattle and use should be limited only to healthy, immunocompetent, unstressed cattle.

Express® is a registered trademark of Boehringer Ingelheim Animal Health USA Inc.

Boehringer Ingelheim Animal Health USA Inc., St. Joseph, MO 64506

Phone: 1 (888) 637-4251

VLN/PCN 124/44B1.20

10 Doses/Rehydrate with 20 mL

This package contains one 10 dose vial of MLV vaccine and one 20 mL vial of diluent.

128501-04

50 Doses/Rehydrate with 100 mL

This package contains one 50 dose vial of MLV vaccine and one 100 mL vial of diluent.

128502-04

CPN: 1028272.2



COLORADO SERUM COMPANY4950 YORK STREET, P.O. BOX 16428, DENVER, CO, 80216-0428Telephone: 303-295-7527Order Desk: 800-525-2065Fax: 303-295-1923Website: www.colorado-serum.comEmail: colorado-serum@colorado-serum.comTHIS SERVICE AND DATA ARE PROVIDED "AS IS". DVMetrics assumes no liability, and each user assumes full risk, responsibility, and liability, related to its use of the DVMetrics service and data. See the Terms of Use for further details.

TETANUS TOXOID-CONCENTRATED

Colorado Serum

Adjuvanted

GENERAL INFORMATION: This product has been shown to be effective for the vaccination of healthy horses, cattle, sheep, goats, and swine against tetanus. This product was licensed prior to the requirement to establish a minimum age for use. The duration of immunity is unknown. For more information regarding efficacy and safety data, see productdata.aphis.usda.gov.

Safety in pregnant animals is unknown.

Tetanus Toxoid is prepared by detoxifying tetanus toxin in such a manner as to allow the antigenic properties to remain intact. Product is purified, concentrated and adjuvanted to provide a low dose effective immunizing agent.

Each serial is tested for purity, safety, and potency in accordance with USDA requirements.

Tetanus is caused by a neurotoxin produced by growth of Clostridium tetani, an anaerobic (lives without air) micro-organism, in necrotic tissue. Affected animals become stiff, have difficulty swallowing, and have an increased pulse rate. Breathing is labored. Spasmodic contractions of the muscular system occur, such as contracting muscles of the jaw.

Spasmodic contractions of the muscular system occur, such as contracting muscles of the jaw. Thus, the term “lockjaw” is often used. Legs and tail are often stiff with abdominal muscles contracted. Tetanus stricken animals may be unusually sensitive to light and heat. Temperature of the animal generally remains normal, elevating only shortly before death.

Protective antibody levels usually occur about two weeks after the second injection of the primary immunization series. In contrast, administration of Tetanus Antitoxin is recommended for immediate, emergency, passive treatment of exposed animals with unknown vaccination history or with signs of tetanus infection.

DIRECTIONS: Do not vaccinate within 21 days before slaughter. Store at 2-8° C. Do not freeze. Do not mix with other products. Shake well before use. Use entire contents when first opened.

PRECAUTIONS: A transitory local reaction may occur at injection site. Anaphylactoid reaction may occur following administration of products of this nature. If noted, administer adrenalin or equivalent. In case of human exposure, consult a physician.

DOSAGE & ADMINISTRATION: For primary immunization, two doses should be administered subcutaneously or intramuscularly approximately 30 days apart. Use intramuscularly for horses as local reactions are more likely to occur if injected subcutaneously.

Horses: 1 ml IM

Cattle: 1 ml SC or IM

Sheep, Goats, Swine: 0.5 ml SC or IM

Historically, annual single dose revaccination has been recommended. Contact veterinarian for advice.

OTHER INFORMATION: Contains thimerosal and formalin as preservatives. Tetanus Toxoid Concentrate is available in single dose size packaged 10 vials to the carton, and in 10 dose vials.

THE PEAK OF QUALITY SINCE 1923

VLN: 188 / PCN: 8601.00

COLORADO SERUM COMPANY, 4950 York Street, Denver, Colorado 80216

303-295-752

www.colorado-serum.com

Contact us for information on other Colorado Serum Company products. Fine Veterinary Products since 1923.

FOR VETERINARY USE ONLY

 

 

Order #

10 - 1 ml vials

10 - 1 dose vials

11411

10 ml

10 doses

11415

CPN: 1101033.3

Products

Dimensions

Care information

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)
View full details

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)